Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C. Becker, Lucie Heinzerling, Peter Mohr et al.|The Lancet|2023Cited by 75
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology GroupImke Grimmelmann, Ralf Gutzmer, M Momma et al.|European Journal of Cancer|2021Cited by 26
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGCindy Franklin, Selma Ugurel, Peter J. Mohr et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 19
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Selma Ugurel, Peter Mohr et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 14
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Michael Weichenthal, Emilie Scherrer et al.|Cancers|2022Cited by 13